CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$45.58 USD
-1.40 (-2.98%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $45.25 -0.33 (-0.72%) 8:08 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,694 | 1,815 | 2,379 | 1,690 | 944 |
Receivables | 200 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 38 | 38 | 26 | 44 |
Total Current Assets | 1,908 | 1,853 | 2,418 | 1,717 | 988 |
Net Property & Equipment | 152 | 164 | 138 | 42 | 31 |
Investments & Advances | 2 | 53 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 14 | 16 | 22 | 18 | 6 |
Total Assets | 2,230 | 2,243 | 2,752 | 1,828 | 1,067 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 38 | 27 | 15 | 9 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 46 | 78 | 92 | 64 | 31 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 0 | 1 | 10 | 12 |
Total Current Liabilities | 109 | 121 | 120 | 94 | 57 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 14 | 12 | 0 | 12 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 6 | 20 | 8 | 14 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 347 | 368 | 352 | 164 | 127 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 2 | 2 | 2 | 2 |
Capital Surplus | 2,878 | 2,735 | 2,598 | 2,236 | 1,162 |
Retained Earnings | -1,000 | -846 | -196 | -574 | -225 |
Other Equity | 2 | -16 | -5 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,883 | 1,875 | 2,399 | 1,664 | 939 |
Total Liabilities & Shareholder's Equity | 2,230 | 2,243 | 2,752 | 1,828 | 1,067 |
Total Common Equity | 1,883 | 1,875 | 2,399 | 1,664 | 939 |
Shares Outstanding | 79.40 | 78.20 | 76.50 | 71.20 | 55.20 |
Book Value Per Share | 23.71 | 23.98 | 31.37 | 23.37 | 17.02 |
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,002 | 2,108 | 1,694 | 1,740 | 1,768 |
Receivables | 0 | 0 | 200 | 0 | 70 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 12 | 14 | 21 | 21 |
Total Current Assets | 2,010 | 2,120 | 1,908 | 1,761 | 1,860 |
Net Property & Equipment | 143 | 147 | 152 | 156 | 159 |
Investments & Advances | 11 | 0 | 2 | 0 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 27 | 21 | 14 | 14 | 14 |
Total Assets | 2,340 | 2,439 | 2,230 | 2,087 | 2,197 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 16 | 38 | 26 | 28 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 92 | 78 | 46 | 67 | 90 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 9 | 9 | 4 | 0 |
Total Current Liabilities | 128 | 119 | 109 | 111 | 133 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 13 | 14 | 14 | 16 | 12 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 1 | 5 | 5 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 359 | 355 | 347 | 359 | 381 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 3 | 3 | 3 | 2 | 2 |
Capital Surplus | 3,224 | 3,199 | 2,878 | 2,821 | 2,799 |
Retained Earnings | -1,243 | -1,116 | -1,000 | -1,089 | -977 |
Other Equity | -3 | -2 | 2 | -7 | -9 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,981 | 2,084 | 1,883 | 1,728 | 1,816 |
Total Liabilities & Shareholder's Equity | 2,340 | 2,439 | 2,230 | 2,087 | 2,197 |
Total Common Equity | 1,981 | 2,084 | 1,883 | 1,728 | 1,816 |
Shares Outstanding | 85.00 | 84.80 | 79.40 | 79.40 | 78.90 |
Book Value Per Share | 23.31 | 24.57 | 23.71 | 21.76 | 23.02 |